68Ga- and 18F-CAIX PET Imaging Study (CAIX-PET)

November 10, 2026 updated by: Peking University First Hospital

A Prospective Randomized Study of 68Ga- and 18F-Labeled CAIX-Targeted PET/CT Imaging in Patients With Renal Tumors

This exploratory clinical imaging study will evaluate the safety, tolerability, biodistribution, lesion detection, and tumor uptake characteristics of 68Ga- and 18F-labeled carbonic anhydrase IX (CAIX)-targeted positron emission tomography/computed tomography (PET/CT) in patients with renal tumors or suspected renal cell carcinoma. Participants will be randomly assigned to receive either 68Ga-CAIX or 18F-CAIX PET/CT. All participants will also undergo 18F-FDG PET/CT for comparison. The study will further explore the association between CAIX-targeted PET findings and CAIX expression assessed by immunohistochemistry, as well as the diagnostic performance of CAIX-targeted PET/CT for lesion detection.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 010000
        • Recruiting
        • Department of Nuclear Medicine, Peking University First Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

- 1. Adults aged 18 years or older. 2. Voluntarily provide written informed consent before participation. 3. Patients with an indeterminate renal mass, suspected renal cell carcinoma, previously diagnosed clear cell renal cell carcinoma, or suspected recurrent renal cell carcinoma based on clinical or imaging findings.

4. Estimated life expectancy of at least 6 months. 5. Participants of childbearing potential must use appropriate and highly effective contraception for at least 35 days after administration of the study tracer.

Exclusion Criteria:

  • 1. Renal tumor known to represent metastasis from another primary malignancy. 2. Other active malignancies requiring treatment. 3. Chemotherapy, radiotherapy, or immunotherapy within 4 weeks before study enrollment.

    4. Renal dysfunction with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m².

    5. Uncontrolled psychiatric disorders that may interfere with study participation.

    6. Pregnancy or breastfeeding. 7. Severe nonmalignant diseases, including infectious, autoimmune, or metabolic diseases, that in the investigator's opinion may interfere with the study objectives, participant safety, or study compliance.

    8. Individuals belonging to vulnerable populations.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 68Ga-CAIX PET/CT

Participants randomized to this arm will receive a single intravenous administration of 68Ga-CAIX followed by PET/CT imaging approximately 1 hour after tracer administration. Participants will also undergo 18F-FDG PET/CT approximately 48 hours before or after the 68Ga-CAIX PET/CT examination according to the randomized imaging sequence.

68Ga-labeled CAIX-targeted PET tracer administered as a single intravenous injection at approximately 0.08-0.10 mCi/kg, followed by PET/CT imaging approximately 1 hour after administration.

Experimental: 18F-CAIX PET/CT

Participants randomized to this arm will receive a single intravenous administration of 18F-CAIX followed by PET/CT imaging approximately 1 hour after tracer administration. Participants will also undergo 18F-FDG PET/CT approximately 48 hours before or after the 18F-CAIX PET/CT examination according to the randomized imaging sequence.

18F-labeled CAIX-targeted PET tracer administered as a single intravenous injection at approximately 0.08-0.10 mCi/kg, followed by PET/CT imaging approximately 1 hour after administration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Semiquantitative Uptake of CAIX-Targeted Tracers
Time Frame: During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.

CAIX-targeted tracer uptake will be quantified using the maximum standardized uptake value (SUVmax) measured by PET/CT in predefined normal organs and tumor lesions.

During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Adverse Events
Time Frame: From tracer administration through 24 hours after PET/CT imaging.

The incidence of adverse events occurring after administration of 68Ga-CAIX or 18F-CAIX will be recorded to assess the safety and tolerability of the CAIX-targeted tracers.

From tracer administration through 24 hours after PET/CT imaging.
Correlation Between CAIX PET Uptake and CAIX Immunohistochemical Expression
Time Frame: Within 4 weeks after PET/CT examination, at the time of pathological evaluation.

The correlation between CAIX PET uptake, measured by SUVmax on CAIX-targeted PET/CT, and CAIX immunohistochemical expression, quantified using the H-score, will be assessed using the Spearman correlation coefficient.

Within 4 weeks after PET/CT examination, at the time of pathological evaluation.
Number of Lesions Detected by CAIX-Targeted PET/CT
Time Frame: During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.

The number of tumor lesions detected by 68Ga-CAIX or 18F-CAIX PET/CT will be recorded and compared with the number of lesions identified by 18F-FDG PET/CT and available clinical, pathological, and imaging reference standards.

During the PET/CT examination, approximately 60 minutes after 18F-CAIX or 68Ga-CAIX administration.
Sensitivity of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

The sensitivity of 68Ga-CAIX or 18F-CAIX PET/CT for detecting tumor lesions will be calculated as the percentage of reference-standard-positive lesions correctly identified by CAIX-targeted PET/CT.

From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
Specificity of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

The specificity of 68Ga-CAIX or 18F-CAIX PET/CT for detecting tumor lesions will be calculated as the percentage of reference-standard-negative lesions correctly identified as negative by CAIX-targeted PET/CT.

From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
Accuracy of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

The accuracy of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of lesions correctly classified as positive or negative according to the clinical, pathological, and imaging reference standards.

From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
False-Positive Rate of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

The false-positive rate of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of reference-standard-negative lesions incorrectly identified as positive by CAIX-targeted PET/CT.

From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.
False-Negative Rate of CAIX-Targeted PET/CT for Lesion Detection
Time Frame: From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

The false-negative rate of 68Ga-CAIX or 18F-CAIX PET/CT for lesion detection will be calculated as the percentage of reference-standard-positive lesions incorrectly identified as negative by CAIX-targeted PET/CT.

From the PET/CT examination until completion of the clinical, pathological, and imaging reference standard assessment, within 4 weeks after PET/CT.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

October 8, 2026

First Posted (Actual)

October 15, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CAIX 001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data underlying the results reported in the study, after de-identification.

IPD Sharing Time Frame

Beginning 12 months after publication of the study results and ending 36 months after publication.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.